Structural highlights
Publication Abstract from PubMed
Double whammy! Small molecules that inhibit Staphylococcus aureus dehydrosqualene synthase (CrtM) or host squalene synthase (SQS) are of interest as novel, innate immunity-based therapeutics, blocking virulence or stimulating antibacterial neutrophil extracellular trap (NET) formation. The discovery of leads that do both represents a new route to treating staph infections.
Dual dehydrosqualene/squalene synthase inhibitors: leads for innate immune system-based therapeutics.,Lin FY, Zhang Y, Hensler M, Liu YL, Chow OA, Zhu W, Wang K, Pang R, Thienphrapa W, Nizet V, Oldfield E ChemMedChem. 2012 Apr;7(4):561-4. doi: 10.1002/cmdc.201100589. Epub 2012 Jan 30. PMID:22290830[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Lin FY, Zhang Y, Hensler M, Liu YL, Chow OA, Zhu W, Wang K, Pang R, Thienphrapa W, Nizet V, Oldfield E. Dual dehydrosqualene/squalene synthase inhibitors: leads for innate immune system-based therapeutics. ChemMedChem. 2012 Apr;7(4):561-4. doi: 10.1002/cmdc.201100589. Epub 2012 Jan 30. PMID:22290830 doi:10.1002/cmdc.201100589
